Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,462 active trials11 approved drugs128 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,252 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05961111 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05812677 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05801783 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer | unknown | Early Phase 1 | 10 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05087264 | Clinical Study of Indocyanine Green Displaying Pelvic Nerve in Radical Operation of Cervical Cancer | unknown | Early Phase 1 | 86 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT03814447 | The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer | unknown | Early Phase 1 | 10 | Shanghai 6th People's HospitalOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT03961412 | A Family-based Intervention to Improve Pap Test Screening Among Under-screened Chinese American Immigrant Women | unknown | Early Phase 1 | 224 | University of Nevada, RenoOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT04503980 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | unknown | Early Phase 1 | 10 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Aug 7, 2020 | clinicaltrials |
| NCT04113096 | Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer | unknown | Early Phase 1 | 104 | The University of The West IndiesOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT04046185 | Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer(ECCT) | unknown | Early Phase 1 | 60 | Shanghai First Maternity and Infant HospitalOTHER | 0 | Aug 6, 2019 | clinicaltrials |
| NCT03799913 | MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | unknown | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT03692637 | Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer | unknown | Early Phase 1 | 30 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 31, 2019 | clinicaltrials |
| NCT02323841 | Feasibility Study: Conservative Treatment in Cervical Cancer | unknown | Early Phase 1 | 30 | Catholic University of the Sacred HeartOTHER | 1 | Dec 24, 2014 | clinicaltrials |
| NCT01779128 | PET-CT vs. Integrated MR-PET Scanning of GYN Cancers | unknown | Early Phase 1 | 100 | Massachusetts General HospitalOTHER | 1 | Jan 30, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2023source: clinicaltrials